Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

Elizabeth A Koller1, James T Cross, P Murali Doraiswamy

  • 1Division of Metabolic and Endocrine Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA.

Pharmacotherapy
|June 25, 2003
PubMed
Summary

Risperidone treatment can cause hyperglycemia, including new-onset diabetes and worsening of existing diabetes. This atypical antipsychotic poses a higher risk of hyperglycemia compared to haloperidol.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital Cognitive Twins in mental health.

Nature. Mental health·2026
Same author

Utility of the Medical Knowledge AI Copilot, OpenEvidence: A Patient With 100 Cerebral Microhemorrhages.

Cureus·2026
Same author

One Hundred Cerebral Microhemorrhages: Rethinking Cerebral Amyloid Angiopathy in the Era of Amyloid-Targeted Antibodies.

Cureus·2026
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

A seven-year longitudinal study of the Alzheimer's disease blood metabolome.

medRxiv : the preprint server for health sciences·2025

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Atypical antipsychotics, such as risperidone, are widely used for psychiatric conditions.
  • Hyperglycemia is a known potential adverse effect of some antipsychotic medications.
  • Understanding the specific risks associated with risperidone is crucial for patient safety.

Purpose of the Study:

  • To investigate the clinical characteristics of hyperglycemia in patients treated with risperidone.
  • To compare the incidence of hyperglycemia associated with risperidone to that of haloperidol.

Main Methods:

  • A pharmacovigilance survey of spontaneously reported adverse events was conducted.
  • Data from the Food and Drug Administration MedWatch surveillance program (1993-2002) were analyzed.

Related Experiment Videos

  • Published cases and haloperidol-associated hyperglycemia reports served as controls.

    • Main Results:

    • 131 reports of risperidone-associated hyperglycemia were identified.
    • 78 patients had newly diagnosed hyperglycemia, and 46 had exacerbated pre-existing diabetes.
    • Hyperglycemia typically appeared within 3 months of risperidone initiation, with varying severity, including four deaths.

    Conclusions:

    • Atypical antipsychotic treatment, including risperidone, can precipitate or unmask hyperglycemia.
    • Risperidone is associated with a relatively higher incidence of hyperglycemia compared to haloperidol.
    • Clinical vigilance for hyperglycemia is warranted in patients receiving risperidone.